FY2025 EPS Estimates for Korro Bio Decreased by Analyst

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Chardan Capital lowered their FY2025 earnings per share estimates for Korro Bio in a research note issued on Wednesday, May 14th. Chardan Capital analyst K. Nakae now expects that the company will post earnings per share of ($10.00) for the year, down from their prior estimate of ($9.68). Chardan Capital has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. Chardan Capital also issued estimates for Korro Bio's FY2026 earnings at ($7.83) EPS.

Korro Bio (NASDAQ:KRRO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.60) by $0.11. The business had revenue of $2.55 million during the quarter, compared to analyst estimates of $0.13 million.

Other research analysts have also issued research reports about the stock. Cantor Fitzgerald raised shares of Korro Bio to a "strong-buy" rating in a research report on Tuesday, April 29th. HC Wainwright decreased their price objective on shares of Korro Bio from $115.00 to $100.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Royal Bank of Canada decreased their price objective on shares of Korro Bio from $105.00 to $95.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 19th. Finally, Oppenheimer decreased their price objective on shares of Korro Bio from $155.00 to $90.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Korro Bio presently has an average rating of "Buy" and a consensus target price of $102.43.

Korro Bio Price Performance

Shares of KRRO stock traded down $1.01 on Monday, hitting $13.80. The company's stock had a trading volume of 55,104 shares, compared to its average volume of 99,280. Korro Bio has a fifty-two week low of $11.13 and a fifty-two week high of $98.00. The firm's fifty day moving average price is $16.21 and its 200-day moving average price is $30.97. The stock has a market capitalization of $129.60 million, a price-to-earnings ratio of -1.46 and a beta of 2.66.

Institutional Investors Weigh In On Korro Bio

Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in shares of Korro Bio by 374.9% during the third quarter. JPMorgan Chase & Co. now owns 12,391 shares of the company's stock worth $414,000 after acquiring an additional 9,782 shares during the period. Rhumbline Advisers boosted its holdings in shares of Korro Bio by 7.8% during the fourth quarter. Rhumbline Advisers now owns 9,602 shares of the company's stock worth $366,000 after acquiring an additional 691 shares during the period. Balyasny Asset Management L.P. bought a new stake in shares of Korro Bio during the fourth quarter worth approximately $220,000. Legal & General Group Plc boosted its holdings in shares of Korro Bio by 664.1% during the fourth quarter. Legal & General Group Plc now owns 4,325 shares of the company's stock worth $165,000 after acquiring an additional 3,759 shares during the period. Finally, Wellington Management Group LLP boosted its stake in shares of Korro Bio by 11.5% in the fourth quarter. Wellington Management Group LLP now owns 14,553 shares of the company's stock valued at $554,000 after buying an additional 1,501 shares during the period. Institutional investors own 13.18% of the company's stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).